Theory Paper IIDrNB Cardiology – Theory Notes
ACUTE PULMONARY EMBOLISM (PE)
IDEFINITION AND THE “SPIRAL OF DEATH” PATHOPHYSIOLOGY
- Definition: Acute Pulmonary Embolism (PE) is the mechanical and vasoconstrictive obstruction of the pulmonary arterial tree by a thromboembolus (originating in 80 to 90 percent of cases from proximal Deep Vein Thrombosis [DVT] of the iliofemoral or popliteal veins).
- The Right Ventricular “Spiral of Death” (ESC 2019):
- Abrupt Afterload Spike: Mechanical occlusion of >30 to 50 percent of the pulmonary vascular bed combined with platelet release of Thromboxane A2 and Serotonin causes an abrupt surge in Pulmonary Vascular Resistance (PVR).
- RV Dilatation and Ventricular Interdependence: Because the thin-walled, unconditioned Right Ventricle (RV) cannot acutely generate a mean PA pressure above 40 mmHg (Peak RVSP >60 mmHg suggests chronic pre-existing PH), the RV dilates acutely, stretching the tricuspid annulus (causing functional TR) and shifting the interventricular septum leftward into the Left Ventricle (“D-shaped LV”) within the rigid pericardium—impairing LV diastolic filling (underloading) and dropping systemic cardiac output.
- RV Myocardial Ischemia and Obstructive Shock: Elevated RV wall tension compresses the intramuscular branches of the Right Coronary Artery (RCA) while systemic arterial hypotension reduces aortic root coronary perfusion pressure, precipitating RV myocardial ischemia/infarction, cardiovascular collapse, and Pulseless Electrical Activity (PEA) arrest.
IIDIAGNOSTIC PROBABILITY SCORES AND D-DIMER ALGORITHMS
- Pre-Test Probability Clinical Prediction Rules (Applied BEFORE Imaging):
- Wells Score for PE: Clinical signs/symptoms of DVT (3.0 pts), PE is #1 diagnosis or equally likely (3.0 pts), Heart rate >100 bpm (1.5 pts), Immobilization >=3 days or surgery in prior 4 weeks (1.5 pts), Previous objectively diagnosed DVT or PE (1.5 pts), Hemoptysis (1.0 pt), and Malignancy treated within 6 months or palliative (1.0 pt). Two-Level Cut-off: Score <=4.0 = “PE Unlikely” (order high-sensitivity D-dimer); Score >4.0 = “PE Likely” (proceed directly to CTPA).
- Revised Geneva Score: Fully objective 8-variable score (excludes the subjective “PE more likely” item).
- PERC Rule (Pulmonary Embolism Rule-Out Criteria): Applied only when pre-test probability is low (<15%); if all 8 criteria are negative (Age <50 yr, HR <100 bpm, SpO2 >=95% on room air, no hemoptysis, no exogenous estrogen use, no prior DVT/PE, no surgery/trauma requiring hospitalization within 4 weeks, no unilateral leg swelling), PE is safely excluded without ordering a D-dimer.
- Specificity-Enhanced D-Dimer Rules (Class IIa):
- Age-Adjusted D-Dimer: In patients over 50 years of age with non-high pre-test probability, the normal D-dimer cut-off of 500 ng/mL (ug/L) is replaced by Age (in years) x 10 ng/mL (e.g., 750 ng/mL in a 75-year-old).
- YEARS Algorithm: Assesses 3 items (Clinical signs of DVT, Hemoptysis, PE most likely diagnosis): if 0 YEARS items are present, PE is excluded if D-dimer <1,000 ng/mL; if >=1 YEARS item is present, PE is excluded if D-dimer <500 ng/mL.
- Pregnancy-Adapted YEARS Algorithm (NEJM 2019 / ESC Class IIa): Combines proximal lower-extremity compression ultrasonography (if DVT symptoms exist) with the 3 YEARS criteria + variable D-dimer (<1,000 ng/mL if 0 items; <500 ng/mL if >=1 item), safely avoiding CTPA radiation in 39 to 65 percent of pregnant women.
IIIPROGNOSTIC RISK STRATIFICATION (ESC 2019 FOUR-TIER MODEL)
- Abandonment of “Massive / Submassive”: Replaced by the ESC 4-Tier Risk Classification integrating (1) Hemodynamic Stability, (2) Clinical Severity (PESI Class III–V or sPESI >=1), (3) Right Ventricular Dysfunction on TTE or CTPA, and (4) Elevated Cardiac Troponin (hs-cTnI/T):
- Simplified PESI (sPESI — 1 Point Each; Score 0 = Low Risk [~1.0% 30-day mortality]; Score >=1 = High Risk [~10.9% mortality]): Age >80 years, History of Cancer, Chronic Cardiopulmonary Disease (HF or COPD), Heart Rate >=110 bpm, Systolic BP <100 mmHg, and Arterial SpO2 <90%.
- Bova Score (0 to 7 Points for Normotensive PE Sub-Stratification): SBP 90–100 mmHg (2 pts), Elevated cardiac troponin (2 pts), RV dysfunction on Echo or CTPA (2 pts), and Heart rate >=110 bpm (1 pt); Stage III (>4 points) predicts a >25 to 40 percent risk of 30-day PE-related complications/hemodynamic collapse.
| ESC Risk Category | Shock or Hypotension | PESI Class III–V or sPESI >=1 | RV Dysfunction (TTE or CTPA) | Elevated Cardiac Troponin | Primary First-Line Management Strategy (ESC Class I) |
|---|---|---|---|---|---|
| High-Risk PE (~5% of PE; >15–30% mortality) | YES (Arrest, obstructive shock, or persistent SBP <90 mmHg) | (+) | YES | (+) | Immediate IV UFH + Systemic Thrombolysis (Class I) (or Surgical/Catheter Embolectomy if lytics contraindicated) |
| Intermediate-High Risk | No | YES | YES (Both Present) | YES (Both Present) | Parenteral/Oral Anticoagulation + ICU/Telemetry Monitoring; Rescue Reperfusion / CDT if deterioration (PEITHO) |
| Intermediate-Low Risk | No | YES | Either One Positive (or Both Negative) | Either One Positive (or Both Negative) | Inpatient Anticoagulation (LMWH/Fondaparinux -> DOAC) |
| Low-Risk PE (~1% mortality) | No | NO (PESI I–II / sPESI = 0) | NO | NO | Direct Oral Anticoagulant (DOAC) + Early Discharge (<24–48 h) / Home Treatment (Class IIa — HoT-PE) |
IVOBJECTIVE ECHOCARDIOGRAPHIC AND CTPA SIGNS OF RV DYSFUNCTION
- Bedside Transthoracic Echocardiography (Mandatory First Test in Unstable Suspected PE):
- RV/LV Basal End-Diastolic Diameter Ratio >= 1.0 with interventricular septal flattening (D-sign).
- McConnell Sign: Akinesia of the mid-free wall of the RV with preserved (normokinetic/hyperkinetic) apical contractility (high specificity >94% for acute PE, though also seen in RV infarction).
- The “60/60 Sign”: Coexistence of a shortened Pulmonary Acceleration Time (PAT) <60 ms (with mid-systolic notching of the RVOT pulsed-wave Doppler envelope) and a Tricuspid Regurgitation Peak Systolic Gradient <60 mmHg (confirming acute pressure load on an unconditioned RV).
- Decreased TAPSE (<16 mm): Independently predicts PE-related mortality.
- Right Heart Thrombus-in-Transit: Mobile serpentine thrombus in the RA/RV or straddling a PFO (present in 4%; carries >20% mortality).
- CT Pulmonary Angiography (CTPA — Diagnostic Gold Standard): Direct intraluminal filling defect (“saddle” or lobar/segmental embolus) with an RV/LV diameter ratio >= 0.9 to 1.0 on 4-chamber view and contrast reflux into the IVC/hepatic veins.
VEVIDENCE-BASED MANAGEMENT AND LANDMARK CLINICAL TRIALS
- Hemodynamic Support in RV Obstructive Shock:
- Judicious Fluid Challenge (<=500 mL Only): Give no more than 500 mL of isotonic crystalloid over 15 to 30 minutes only in patients with low central venous pressure; aggressive volume loading over-distends the RV, shifts the septum further into the LV, increases RV wall stress/ischemia, and worsens shock.
- Vasopressors and Inotropes: Norepinephrine (0.1 to 1.0 mcg/kg/min) is the first-line vasopressor (restores aortic root RCA perfusion pressure and improves systemic RV-LV interaction), supplemented with Dobutamine (2 to 10 mcg/kg/min) or Inhaled Nitric Oxide if cardiac output remains low; VA-ECMO serves as a bridge to surgical or mechanical embolectomy in refractory cardiac arrest/shock.
- Anticoagulation Regimens (Class I):
- Parenteral: LMWH (Enoxaparin 1 mg/kg SC q12h) or Fondaparinux is preferred over Unfractionated Heparin (UFH: 80 U/kg bolus + 18 U/kg/h) except in High-Risk PE with shock, severe renal failure (CrCl <30 mL/min), or severe obesity.
- First-Line Single-Drug DOAC Regimens (AMPLIFY & EINSTEIN-PE Trials): Apixaban (10 mg BD for 7 days, then 5 mg BD) or Rivaroxaban (15 mg BD for 21 days with food, then 20 mg OD) (whereas Dabigatran 150 mg BD and Edoxaban 60 mg OD require 5 days of initial parenteral heparin). (DOACs are contraindicated in pregnancy, severe renal failure, and triple-positive Antiphospholipid Syndrome.)
- Extended Secondary Prevention (>6 Months — AMPLIFY-EXT & EINSTEIN CHOICE Trials): After 6 months of treatment for unprovoked PE, reduced-dose Apixaban 2.5 mg BD or Rivaroxaban 10 mg OD reduces recurrent VTE by ~80 percent without increasing major bleeding.
- Systemic Thrombolysis and Catheter-Directed Therapies (CDT):
- High-Risk PE (Class I): Alteplase (rt-PA) 100 mg IV over 2 hours (or 0.6 mg/kg [max 50 mg] over 15 minutes / 50 mg IV bolus in cardiac arrest).
- PEITHO Trial (NEJM 2014 — Why Routine Lytics are Class III in Intermediate-High Risk PE): In 1,005 normotensive Intermediate-High Risk PE patients, weight-based Tenecteplase reduced 7-day death or hemodynamic collapse (2.6% vs. 5.6%; p = 0.02), but caused a 5-fold increase in major extracranial bleeding (6.3% vs. 1.2%) and a 10-fold increase in hemorrhagic/ischemic stroke (2.4% vs. 0.2%) with zero difference in 30-day mortality or late CTEPH—restricting systemic thrombolysis in intermediate-risk PE strictly to rescue therapy if hemodynamic decompensation occurs.
- Catheter-Directed Therapies (ULTIMA, OPTALYSE-PE, FLARE/FLASH, and PEERLESS Trials): Ultrasound-Facilitated Catheter-Directed Thrombolysis (USCDT / EKOS: 4 to 12 mg total Alteplase per lung) (ULTIMA, OPTALYSE-PE) and Large-Bore Mechanical Aspiration Thrombectomy (FlowTriever / Indigo) (FLARE, FLASH) rapidly reverse RV/LV dilation with <1.5% major bleeding. In the head-to-head randomized PEERLESS Trial (Circulation 2024, n = 550 intermediate-high risk PE), Large-Bore Mechanical Thrombectomy (FlowTriever) proved superior to Catheter-Directed Thrombolysis for the primary hierarchical win-ratio endpoint (driven by significantly fewer clinical deteriorations/bailouts [1.8% vs. 5.4%] and less ICU admission/length of stay, with similar mortality and intracranial bleeding).
- Post-PE Syndrome and CTEPH Screening (Class I): Every acute PE survivor must be evaluated at 3 to 6 months post-PE; persistent dyspnea or functional limitation warrants Transthoracic Echocardiography and a Ventilation/Perfusion (V/Q) lung scan (not CTPA alone) to rule out Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Key references
- Konstantinides SV, Meyer G, Becattini C, et al.: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism, European Heart Journal, 2020.
- Meyer G, Vicaut E, Danays T, et al. (PEITHO Investigators): Fibrinolysis for patients with intermediate-risk pulmonary embolism, New England Journal of Medicine, 2014.
- Jaber WA, Gonsalves CF, Stortecky S, et al. (PEERLESS Investigators): Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial, Circulation, 2024.
- Barco S, Schmidtmann I, Ageno W, et al. (HoT-PE Investigators): Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial, European Heart Journal, 2020.
meritmedscript.comDr. Sidhartha Mullapudi
